GlassScriptPhysician profile
Marium Mujahid
NPI 1336553528
$544.52
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.37 · 2020: $59.90 · 2021: $218 · 2022: $250.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $191.01 | 2019-2022 | |
| Lilly USA, LLC | $109.04 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $81.24 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.24 | 2020-2022 | |
| Pfizer INC. | $39.09 | 2021-2022 | |
| Glaxosmithkline, LLC. | $31.58 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $25.27 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.97 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.08 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marium Mujahid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.